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ABSTRACT
Introduction: Chronic inflammatory
rheumatic diseases (RDs) trigger high costs for
healthcare systems and society due to the
disability and comorbidity associated with
these disease entities. The aim of this study
was to analyze patients with RD, assess the use
of conventional synthetic and biologic
therapies, and estimate the overall cost of
treatment in Italy.
Methods: Administrative healthcare claims
from the Piedmont region in Northwest Italy
were reviewed to identify patients who received
disease-modifying antirheumatic drugs
(DMARDs) between 2007 and 2010.
Confirmation of RD was based on: (1)
diagnosis-specific exemption code; (2)
hospitalization or emergency care events
characterized by disease-specific ICD9 codes;
(3) inclusion in the regional registry of biologic
drugs. The follow-up period was 3 years.
Results: A total of 9560 subjects, of whom the
majority were women (58.1%), were entered
into the study; the average age of the study
population was 55.3 years. On the index date
12.9% of patients were receiving a biologic
DMARD, with adalimumab the most
frequently prescribed biologic DMARD (4.7%),
followed by etanercept (4.4%). The average total
healthcare expenditure was €377.98 per patient
per month (patient-month). In the subgroup
analysis of healthcare costs according to use of
biologics, the total expenditure was €1037.97/
€230.86 patient-month for those receiving/not
receiving at least one biologic DMARD. In the
subgroup analysis of healthcare costs according
to type of biologic used, the total expenditure
ranged from €657.61 (golimumab) to €1384.15
(rituximab) patient-month.
Conclusions: A substantial difference in the
total costs according to treatment/no
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treatment with a biologic and the specific
biologic DMARD prescribed was identified.
However, this result should be interpreted
with caution as a bias in terms of patient
selection was most likely present. The results
of this study shed some light on RD in an
relevant sample of Italian patients. The
preliminary conclusions need to be confirmed
by further analysis.
Keywords: Antirheumatic drugs; Biologics;
Burden of disease; Italy; Rheumatic diseases
INTRODUCTION
Inflammatory rheumatic diseases (RDs) in
general and rheumatoid arthritis, psoriatic
arthritis, and ankylosing spondylitis
specifically are chronic systemic disorders
which significantly affect patients’ quality of
life. These pathologies are debilitating and
progressive and are associated with severe
functional impairment and pain [1, 2]. The
worldwide prevalence of RDs is high (about 1%)
[3–6], with rheumatoid arthritis alone
accounting for 0.3–1% of all RDs identified [7].
First-line treatments for inflammatory RDs
include non-steroidal anti-inflammatory drugs,
conventional disease-modifying anti-rheumatic
drugs (DMARDs; e.g., methotrexate), and
corticosteroids; immunosuppressants and
systemic corticosteroids are also used [8–13].
In the last 15 years the development of biologic
drugs, such as infliximab, etanercept,
adalimumab, certolizumab, golimumab,
tocilizumab, rituximab, anakinra, abatacept,
and ustekinumab, has resulted in a significant
improvement in the prognosis of rheumatic
patients. Patients who are intolerant to the
chosen treatment or show an inadequate
response (IR) to traditional synthetic DMARDs
are often treated with a biologic drug [14–17].
The treatment of rheumatic patients with an IR
to DMARDs alone usually consists of
combination therapy with a biologic and
traditional DMARD, primarily methotrexate;
however, a number of biologics have been
shown to be efficacious and approved for
monotherapy [18–20].
The aim of this study was to analyze the
characteristics of patients with rheumatoid
arthritis, psoriatic arthritis, and ankylosing
spondylitis in Italy, assess the use of
conventional synthetic and biologic DMARDs,
and estimate the overall cost of managing these
patients within the framework of the Italian
National Health Service (NHS).
METHODS
The data for this analysis was based on the
administrative healthcare claims of the
Piedmont region, which is located in
Northwest Italy and is the second largest
administrative region by area in Italy and the
sixth largest by number of inhabitants (about
4.4 million) [21]. Due to the administrative
nature of the data used, all data was
de-identified, and no clinical or personal
information was available.
An information network is maintained in
each Italian administrative region that
routinely records the healthcare expenditures
for services covered by the NHS. The
pharmaceutical registry for each region
routinely records the costs of dispensing drugs
to those registered in the system. Data available
for each prescription claim include the patient’s
national health number, the Anatomical
Therapeutic Chemical Classification System
code (ATC) [22] of the drug dispensed, the
number of packages dispensed, the number of
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units per package, the dose, the unit cost per
package, and the prescription date. The
outpatient services registry tracks all laboratory
investigations, instrumental tests, and specialist
visits. These databases were analyzed along with
the database of hospital admissions (SDO),
emergency care and the regional registry of
biologic drugs in rheumatology. The RDs
considered were rheumatoid arthritis, psoriatic
arthritis and ankylosing spondylitis. The study
population was identified as patients who
received at least one prescription of a
synthetic or biologic DMARD during the
period between 1 January 2007 and 31
December 2010. The first prescription
represented the index date for each patient.
The biologic drugs considered in the study
were: etanercept (ATC: L04AB01), infliximab
(ATC: L04AB02), adalimumab (ATC: L04AB04),
certolizumab (ATC: L04AB05), golimumab
(ATC: L04AB06), tocilizumab (ATC: L04AC07),
rituximab (ATC: L01XC02), anakinra (ATC:
L04AC03), abatacept (ATC: L04AA24), and
ustekinumab (ATC: L04AC05).
The synthetic DMARDs considered were:
methotrexate (ATC: L01BA01; L04AX03),
azathioprine (ATC: L04AX01), leflunomide
(ATC: L04AA13), sulfasalazine (ATC:
A07EC01), and hydroxychloroquine (ATC:
P01BA02).
The data were analyzed with the aim to link
subjects to a diagnosis of the RD of interest
(rheumatoid arthritis, psoriatic arthritis,
ankylosing spondylitis). For a diagnosis of the
target RD, at least one of the following criteria
had to be met: (1) diagnosis-specific exemption
code; (2) hospitalization or emergency care
events marked with disease-specific ICD9
codes (696.0 and 696.1 for psoriatic arthritis;
714.0, 714.1, 714.2, 714.30, 714.32, and 714.33
for rheumatoid arthritis; 720.0 for ankylosing
spondylitis) (3) inclusion in the special
rheumatology registry of biologic drugs. In
addition, patients who received at least one
prescription of methotrexate or leflunomide in
the 3 years of analysis were considered to be
rheumatic patients and included in the analysis.
Patient data were anonymously linked and
imported into STATA version 13.1 (StataCorp,
College Station, TX), and clinical (comorbidity),
pharmacological (treatment pattern), and
economic (total healthcare costs) indicators
were analyzed. Each patient was followed from
the index date up to 3 years. The total
healthcare cost was estimated taking drug
prescription (synthetic and biologic DMARDS
and co-medications), hospital, and outpatient
costs into account. The cost analysis was
developed for the entire population and also
for subgroups of patients identified on the basis
of biologic DMARD use.
RESULTS
In total, 12,455 subjects with at least one
prescription for a synthetic or biologic
DMARD was identified in the period
2007–2010. Of these, 2895 subjects were
excluded because they did not meet any of the
conditions required for a confirmed RD. The
category of indistinct RD was defined to include
those cases in which, despite the certainty of
the presence of RD, it was not possible to assign
the condition to one of the three rheumatic
diseases of interest. This category included
patients with a discordant definition of more
than one disease of interest (n = 584; 4.7%),
those who were identified as RD patients only
on the basis of a prescription for methotrexate
(n = 710; 5.7%), and those with juvenile
idiopathic arthritis (n = 6;&0.0%). Following
exclusion of those who did not meet the
inclusion criteria, the overall study population
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consisted of 9560 patients, among whom 1855
had psoriatic arthritis (19%), 5989 had
rheumatoid arthritis (63%), and 416 had
ankylosing spondylitis (4%). The majority of
patients were women (58.1%), and the mean
[±standard deviation (SD)] age of the study
population was 55.3 (±17.4) years. The analysis
of presence of comorbidity in the study
population (N = 9560) is shown in Table 1.
Of the 9560 patients entered into the study,
4153 (43%) reported at least one hospitalization
between the index date and the end of the
3-year observation period, among whom were
2655 of the 5989 patients with rheumatoid
arthritis (44%), 149 of the 416 patients with
ankylosing spondylitis (36%), and 651 of the
1885 patients with psoriatic arthritis (35%). Of
the 1300 patients diagnosed with indistinct RD,
698 (54%) reported at least one hospitalization
during the index date and the end of the 3-year
observation period.
On the index date 12.9% of the study
population were receiving a biologic DMARD.
The distribution of all prescriptions on the
index date is shown in Table 2. The total study
population of 9560 patients received 9963
prescriptions in the first year (some patients
received more [1 biologic DMARD). The












Cardiopathy 43 0.45 1.04
Conduction disorders 37 0.39 0.89
Arrhythmias 253 2.65 6.09
Heart failure 153 1.60 3.68
Other undeﬁned heart diseases 48 0.50 1.16
Myocardial infarction 87 0.91 2.09
Other acute and subacute forms of
ischemic heart disease
62 0.65 1.49
Previous myocardial infarction 73 0.76 1.76
Angina pectoris 52 0.54 1.25
Other forms of ischemic heart disease 151 1.58 3.64
Cerebrovascular disease 278 2.91 6.69
Hypercholesterolemia 100 1.05 2.41
Hyperuricemia 19 0.20 0.46
Infections 332 3.47 7.99
Diabetes mellitus 305 3.19 7.34
Neoplasms 688 7.20 16.57
Obesity 106 1.11 2.55
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highest number of prescriptions were written
for methotrexate (46.6%) and
hydroxychloroquine (30.7%); the mostly
highly prescribed biologic DMARDs were
adalimumab (4.7%) and etanercept (4.4%).
Tocilizumab, certolizumab, golimumab, and
ustekinumab were not available in Italy on the
index date and therefore not prescribed at that
time.
The prescription of concomitant
medications during the 3 years of follow-up
was also analyzed, revealing that concomitant
medications were used by 92.5% of the study
population in follow-up year 1, 97.2% in
follow-up year 2, and 97.5% in follow-up year
3 (Table 3). The highest number of prescriptions
was for non-steroidal anti-inflammatory drugs
(60.4–59.6%) and corticosteroids (58.3–57.7%).
The total monthly healthcare expenditure
for hospitalizations, emergency care, outpatient
care, and pharmacological therapy (synthetic
and biologic DMARDs, concomitant drugs) was
assessed for the study population during the
3 years of follow-up. The total expenditure was
€377.98 per patient per month (patient-month),
attributable to the costs of synthetic DMARDs
(€17.03), biologic DMARDs (€149.75),
concomitant medications (€61.07), emergency
care (€4.55), hospitalization (€92.61), and visits
(€52.96) (Table 4).
The mean cost per patient per month was
analyzed in the subgroups of patients who
received or did not receive at least one
prescription of biologic DMARD in a specific
year. During years 1, 2, and 3 of the follow-up
17.7%, 17.5%, and 19.4% of patients,
respectively, had at least one prescription for a
biologic DMARD. The mean total cost per
patient per month including the cost of
biologics was €1037.97 (€1061.20, €1002.23
and €1050.48 in years 1, 2, and 3, respectively,
of the follow-up) (Fig. 1). The cost of biologic
DMARDs was the most important component
of this total expenditure, totaling €821.54
(€829.17, €798.27. and €837.17 in years 1, 2,
and 3, respectively, of the follow-up). The mean
total cost per patient per month in the subgroup
of patients who did not have prescriptions for
biologic DMARDS was €230.86 (€241.25,
€222.58 and €228.74 in years 1, 2, and 3,
respectively, of the follow-up). In this
subgroup the cost for hospitalization was the
most important component of the healthcare
expenditure, totaling €94.64 (€99.42, €90.40
and €94.10 in years 1, 2, and 3, respectively, of
the follow-up).
The average monthly total cost per patient
was also analyzed by stratifying the cohort on
Table 2 Number of prescriptions on the index date in the




















Total number prescriptions 9963
DMARD Disease-modifying antirheumatic drugs
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the basis of the specific biologic DMARD
received. In this subgroup analysis, the total
cost per patient per month ranged from a low of
€657.61 (golimumab) to a high of €1384.15
(rituximab) (Table 5).
DISCUSSION
Rheumatoid arthritis, psoriatic arthritis, and
ankylosing spondylitis are immune-mediated
inflammatory diseases that lead to severe
functional impairment, pain and a significant
decrease in quality of life. These pathologies
determine a relevant economic burden for
healthcare services because of significant
epidemiological impact [3–6].
The aim of this study was to analyze the
characteristics, treatment patterns, and
emerging costs of rheumatic patients. In total,
we identified 9560 patients who had been
prescribed at least one synthetic or biologic
DMARD in the period 2007–2010. The
prevalence of comorbidities was generally low
in the study population and similar to that
reported in the general population. When the
prevalence of Comorbidities was analyzed in
the subgroup of patients who had at least one
hospitalization during the study period, we
noted that it was consistently higher, possibly
indicating a correlation between the comorbid
condition and need for hospital care. The most
commonly prescribed DMARDs were
methotrexate and hydroxychloroquine (46.6
and 30.7% of prescriptions, respectively). The
use of biologic DMARDs was in general low,
with only about 13% of the cohort receiving
them on the index data. The most commonly
prescribed biologic DMARDS were adalimumab
and etanercept.
Degli Esposti and colleagues analyzed the use
of healthcare resources in 1219 patients with
rheumatoid arthritis, psoriatic arthritis,
ankylosing spondylitis, Crohn’s disease,
psoriasis, and ulcerative colitis [23]. The mean
age (±SD) of their study population was 49.6
(±14.6) years, 47% were men, and all patients
were treated with biologic drugs (34% with
adalimumab, 51% with etanercept, and 15%
with infliximab). The data on these patients
were derived from the administrative databases
Table 3 Prevalence of prescriptions for concomitant drugs in the study population (n = 9560) during the 3-year follow-up
Concomitant drugs Patients (n) Prevalence (%)
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Antihypertensives 330 339 355 3.5 3.7 3.9
Hypouricemic agents 492 522 558 5.1 5.6 6.2
Statins 1128 1290 1366 11.8 13.9 15.1
Anti-diabetics 733 798 845 7.7 8.6 9.3
Anti-coagulants 923 977 1003 9.7 10.5 11.1
Anti-platelets 1318 1438 1502 13.8 15.5 16.6
Non-steroidal anti-inﬂammatories 5779 5543 5412 60.4 59.7 59.6
Analgesics 1642 1750 1907 17.2 18.9 21.0
Corticosteroids 5570 5278 5234 58.3 56.9 57.7
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of five local health units in Italy
(Emilia-Romagna, Lazio, Tuscany, Campania,
and Lombardy). The analysis of these authors
revealed that the overall mean annual total
healthcare expenditure for each patient was of
€11,120, of which non-pharmacological costs
were €1177 (10.58%) and pharmacological costs
were €9943 (89.42%). This total expenditure is
significantly higher than that determined in our
study population (about €4500 patient-year).
One possible explanation for this difference is
that the rate of use of biologic DMARDs was
higher in the study of Degli Esposti et al. [23]; it
may be that the cost of these drugs drove up the
overall estimate. When we compare the total
costs which we estimated in the subgroup of
patients who received at least one prescription
of biologic DMARDs (around €1000
patient-month) to the estimate of Degli
Esposti and colleagues, the costs seem to be
more aligned.
Based on our data it appears that a
substantial difference exists in the total costs
of patients treated with different biologic
DMARDS, with a range of about €650 to €1380
patient-month. Beyond the effect of different
prices for the different biologic DMARDS, this
difference could be explained by an implicit
treatment algorithm applied by the clinicians
during the study period. For example, it can be
assumed that only severe and difficult to treat
patients who had been not responding to other
classes of biologic DMARDS were prescribed
rituximab—the reasoning being that this drug is
not recommended as a first-line biologic in
clinical guidelines. As a consequence, patients
treated with rituximab in our study probably,
on average, were in a more advanced stage of
disease progression, had received different lines
of treatment prior to being placed on rituximab,
and had clinically complex disease in
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biologics. This line of reasoning could explain
the high costs for concomitant medication,
emergency care, hospitalizations that,
compared with those related to other
treatments, appear to be driving the higher
total cost. From another point of view, it seems
reasonable to believe that products launched in
more recent years were used only in patients
who received older treatments first due to the
time usually necessary for new products to be
considered part of the routine clinical practice.
Finally, it should be considered that the route of
administration (e.g. intravenous vs.
subcutaneous) plays an important role in the
selection of the treatment as the treating
physician must take into account the
characteristics of the patient (e.g., presence of
disability) and the aggressiveness of the disease.
We therefore suggest that the total healthcare
costs of the patients treated with different
biologic DMARDs in our analysis should be
interpreted with caution as they were probably
biased by the selection of the patients. The main
limitation of the study is the lack of an analysis
which adjusts for such baseline characteristics;
such an adjustment was not possible given the
administrative (and not clinical) nature of the
database used.
CONCLUSION
The results of this study shed some light on the
healthcare cost of rheumatic patients treated in
Italy with biologic DMARDs. The prevalence of
comorbidities in our study population was
generally low and similar to the distribution
reported in the general population, but our
results do suggest the existence of a possible
correlation between the comorbid condition
and need for hospital care. The use of biologic
DMARDs was generally low, with only about
13% of the cohort receiving them on the index
data, but they had a major impact on the total
healthcare expenditure. A substantial
difference, however, seems to exists in the
total costs of patients treated with different
Fig. 1 Average
healthcare expenditure
per patient per month
according to whether a
patient received






speciﬁc year of the
follow-up
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biologic DMARDS. These preliminary results
need to be confirmed by further analysis.
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